InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the ...
GlobalData on MSN
FDA approves AstraZeneca’s Saphnelo for SLE
The approval is supported by results from the Phase III TULIP-SC trial.
Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...
SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...
SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...
Over the past two decades, management of pain in patients with systemic lupus erythematosus (SLE) has come to rely less on higher-risk therapies like opioids, although prescribing intensity remains ...
When people with systemic lupus erythematosus (SLE) actively participate in shared decision-making (SDM) about their disease with their doctors’, trust is likely to increase. A new study found that ...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...
The SLECRISK tool for predicting cardiovascular disease among patients with systemic lupus erythematosus produces more accurate predictions compared with the American College of Cardiology/American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results